Ignite Creation Date:
2024-07-17 @ 11:39 AM
Last Modification Date:
2024-10-26 @ 3:33 PM
Study NCT ID:
NCT06485635
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-07-03
First Post:
2024-06-10
Brief Title:
Real-life-persistence to Antifibrotic Treatments
Sponsor:
Boehringer Ingelheim
Organization:
Boehringer Ingelheim
Study Overview
Official Title:
Real-life-Persistence to Antifibrotic Treatments
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
REPEAT
Brief Summary:
This study will help to better understand the persistence rate to antifibrotic AF treatment in real life in France and to identify potential areas for improvement by investigating the factors associated with a non-persistence rate to AF treatment
Primary objective of the study is to measure the percentage of patients still treated up to 30 months after AF treatment initiation
Primary objective of the study is to measure the percentage of patients still treated up to 30 months after AF treatment initiation
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None